GE HealthCare (GEHC) announces that it has entered into an agreement to acquire Intelligent Ultrasound's AI software business to strengthen its ultrasound portfolio.
GE HealthCare's (GEHC) MIM Software introduced the MIM Symphony HDR Prostate to provide direct tumor visualization using MRI images during live ultrasound procedures for HDR prostate treatments.
GE HealthCare's near-term outlook creates near-term execution risk given the need for a strong 2H'24 ramp, but the longer-term potential may be underrated by the Street. GE HealthCare is a strong #2 in imaging behind Siemens Healthineers; while the company lags in photon-counting CT, its silicon-based approach could be the better one long term. I believe the Street is underestimating the potential of new markets in ultrasound (PoC, surgery, and peripheral), as well as high-margin growth in PDx tied to Alzheimer's, cardiology, and oncology.
GE Healthcare Technologies, Inc. GEHC, in collaboration with the University of Cincinnati (UC), UC Health, and Cincinnati Children's, has announced a cutting-edge initiative to accelerate MRI innovation. This collaboration will provide a well-established MRI Research and Development (R&D) center of excellence on UC's medical campus, enabling direct interaction between clinical investigators and GE HealthCare scientists.
GE HealthCare's (GEHC) latest collaboration is likely to enable clinicians to perform complex cardiology interventions with a high level of precision and improved image quality.
GE HealthCare's (GEHC) latest successful first installation and clinical cases using the OmnifyXR are likely to improve clinical and operational outcomes for both patients and clinicians.
With the growing influence of GenAI in the MedTech sector, innovators like ZBH, GEHC and MDT are poised to thrive.
GE HealthCare's (GEHC) latest agreement is likely to standardize care protocols and improve the quality of CT, MR and ultrasound examinations.
GE HealthCare Technologies shares have dropped 16.8% since March, driven by concerns about management hitting guidance for 2024. Revenue for the company declined 1.2% in Q1 2024 compared to the same period last year, with a drop in product sales. Despite the recent underperformance, the stock is still considered cheap and may warrant a higher price in the future.
Despite being unwanted and unloved, spinoff stocks are often excellent stocks to buy and hold. Since investors bought shares in the parent company, they are often not interested in the business.
GE HealthCare (GEHC) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.